Akari Therapeutics Plc (AKTX) - Dilution Analysis

10-Q filing | 91567.0M shares outstanding

S-1 filing: This S-1 filing describes a best-efforts offering by Akari Therapeutics, PLC of American Depositary Shares (ADSs), Series H warrants, Series I warrants, and pre-funded warrants, subject to completion.

10-K filing | 91567.0M shares outstanding

S-1 filing: This prospectus relates to the offer and sale, by the selling stockholders, of up to 34,680,906 American Depositary Shares representing 69,361,812,000 Ordinary Shares.

8-K filing: Akari Therapeutics, Plc entered into a securities purchase agreement for a registered direct offering and concurrent private placement, issuing ADSs and warrants to institutional investors, directors, and officers, and also exchanged unsecured promissory notes for pre-funded warrants and note exchange warrants. ($5.97M proceeds)

S-1 filing: This is an S-1 filing for an offering of ordinary shares by selling shareholders, including shares issuable upon the exercise of Series E Warrants, Series F Warrants, and Placement Agent Warrants.

8-K filing: Akari Therapeutics, Plc entered into a securities purchase agreement for the issuance and sale of 3,125,000 American Depositary Shares (ADSs) along with warrants in a registered direct offering, expecting gross proceeds of approximately $2.5 million. ($2.5M proceeds)

10-Q filing | 62943.9M shares outstanding

S-3 filing: Akari Therapeutics, PLC may offer to sell ordinary shares, represented by American Depositary Shares, or ADSs, warrants, and units, with the aggregate initial offering price not to exceed $75 million.

10-Q filing | 64352.7M shares outstanding

S-3 filing: S-3 filing on 2025-05-06 registers additional shares for potential issuance due to stock splits, dividends, recapitalizations, or other capital adjustments, pursuant to Rule 416(a).

10-K filing | 57753.0M shares outstanding

10-Q filing | 49517.1M shares outstanding

8-K filing: Akari Therapeutics, Plc entered into a securities purchase agreement to sell and issue 1,713,402 unregistered American Depository Shares and Series D Warrants in a private placement for gross proceeds of $3.2 million, with different pricing for certain investors. ($6.4M proceeds)

S-3 filing: The Registration Statement covers the resale by certain selling securityholders of up to an aggregate of 10,782,431 American Depositary Shares of the Company representing up to an aggregate of 21,564,862,000 ordinary shares, par value US$0.0001 per share of the Company.

10-Q filing | 23906.9M shares outstanding

8-K filing: Akari Therapeutics, Plc entered into a Purchase Agreement for a private placement, closing on May 31, 2024, involving the sale of American Depository Shares (ADSs) and warrants. ($0.01M proceeds)

10-Q filing | 15847.4M shares outstanding

10-K filing | 15847.4M shares outstanding

8-K filing: Akari Therapeutics, Plc closed a private placement on December 29, 2023, selling 947,868 American Depository Shares (ADSs), each representing 2,000 ordinary shares, at $2.11 per ADS to existing investors, including the Company's Chairman and a Director. ($2.0M proceeds)

POS AM filing: This prospectus relates to the resale, by the selling shareholders identified in this prospectus, of up to an aggregate of 136,184,200 ordinary shares represented by 68,092 American Depository Shares, consisting of (1) 118,421,300 ordinary shares represented by 59,211 ADSs, issuable upon the exercise of warrants issued in a private placement in July 2019, or the Private Placement, and (2) 17,762,900 ordinary shares represented by 8,881 ADSs issuable upon the exercise of placement agent warrants issued in connection with the Private Placement.

POS AM filing: This POS AM filing relates to the offering of ordinary shares represented by ADSs issuable upon exercise of series A and series B warrants originally issued in a private placement.

F-3 filing: This F-3 filing outlines the offering of ordinary shares represented by ADSs by selling shareholders. It provides details on the number of shares owned before and after the offering, with beneficial ownership based on 11,305,953,523 ordinary shares outstanding as of October 13, 2023.

POS AM filing: This POS AM filing relates to the potential issuance of ordinary shares represented by ADSs upon the exercise of warrants by selling shareholders, originally issued in a private placement.

POS AM filing: A selling stockholder may not exercise the warrants to the extent such exercise would cause such selling stockholder, together with its affiliates, to beneficially own a number of ordinary shares which would exceed 4.99% or 9.99% of our then outstanding ordinary shares following such exercise.

20-F filing | 4759.7M shares outstanding

F-1 filing: This F-1 filing relates to the registration of ordinary shares represented by American Depositary Shares (ADSs) issuable upon the exercise of warrants held by selling shareholders. The company will not receive any proceeds from the sale of these shares.

20-F filing | 3847.3M shares outstanding

POS AM filing: This POS AM filing relates to the offering of American Depositary Shares (ADSs) by a selling stockholder, Aspire Capital Fund, LLC, under existing Purchase Agreements. The company has the right to sell up to $50.0 million of ADSs to Aspire Capital under each Purchase Agreement, subject to certain conditions and limitations.

POS AM filing: This POS AM filing registers the sale of 2,285,022,800 ordinary shares represented by 22,850,228 ADSs by the selling stockholder, Aspire Capital, pursuant to existing purchase agreements.

POS AM filing: The filing relates to the potential sale of ordinary shares represented by ADSs or warrants or placement agent warrants by selling shareholders, subject to certain ownership limitations.

POS AM filing: This POS AM filing registers the sale of ADSs by a selling stockholder, Aspire Capital Fund, LLC, pursuant to purchase agreements. Aspire Capital is committed to purchase up to an aggregate of $20.0 million and $30.0 million of Akari Therapeutics, Plc ADSs represented by ordinary shares.

F-3 filing: The company entered into securities purchase agreements for the issuance of 7,947,529 ADSs in a private placement at $1.55 per ADS for gross proceeds of approximately $12.3 million. The company also issued compensation warrants to the placement agent with an exercise price of $2.32 per ADS.

POS AM filing: This POS AM filing registers the sale of American Depositary Shares (ADSs) by a selling stockholder, Aspire Capital Fund, LLC, and includes details of purchase agreements where Aspire Capital is committed to purchase up to $50 million of ADSs. The company will not receive proceeds from the sale of ADSs by the selling stockholder.

POS AM filing: This POS AM filing registers the sale of 2,285,022,800 ordinary shares represented by 22,850,228 ADSs by Aspire Capital pursuant to purchase agreements. The company may direct Aspire Capital to purchase up to $50 million of ADSs under each purchase agreement when the ADS price exceeds $0.25.

POS AM filing: A selling stockholder may sell ordinary shares represented by ADSs or warrants or placement agent warrants, subject to certain ownership limitations.

POS AM filing: Akari Therapeutics, Plc is offering 2,285,022,800 ordinary shares represented by 22,850,228 American Depositary Shares (ADSs) through an equity line with Aspire Capital, with Aspire Capital committed to purchase up to $50 million of ADSs at a price not less than $0.25 per ADS.

20-F filing | 3847.3M shares outstanding

F-3 filing: The filing is an F-3 form registering ordinary shares, including ADSs, warrants, subscription rights, debt securities, and units for a total offering amount of $100,000,000.

POS AM filing: This POS AM filing relates to the offering of American Depositary Shares (ADSs) by a selling stockholder, Aspire Capital Fund, LLC, pursuant to purchase agreements. Aspire Capital is committed to purchase up to an aggregate of $20.0 million of our ADSs represented by ordinary shares over the approximately 30-month term of the Purchase Agreement. On June 30, 2020, we entered into a Purchase Agreement with Aspire Capital, which provides that, upon the terms and subject to the conditions and limitations set forth therein, Aspire Capital is committed to purchase up to an aggregate of $30.0 million of our ADSs represented by ordinary shares over the approximately 30-month term of the Purchase Agreement. The company will use the proceeds from the sale of ADSs to research and development, regulatory affairs and clinical trial expenditures and for general corporate purposes, including working capital.

POS AM filing: This POS AM filing registers the sale of ADSs (American Depositary Shares) by a selling stockholder, Aspire Capital, with the company not receiving proceeds from these sales but having received and potentially receiving additional proceeds from prior sales to the same stockholder. The filing also details purchase agreements with Aspire Capital, outlining terms for future ADS purchases and related considerations.

POS AM filing: Akari Therapeutics, Plc is filing a POS AM to register the sale of ADSs by the selling stockholder, Aspire Capital Fund, LLC, and to register the sale of additional ADSs to Aspire Capital under existing purchase agreements.

F-1 filing: This F-1 filing registers 12,650,228 American Depositary Shares (ADSs) representing 1,265,022,800 ordinary shares for sale by a selling stockholder and also covers a purchase agreement for up to $30 million of ADSs with Aspire Capital Fund, LLC.

POS AM filing: The filing relates to the potential exercise of warrants and placement agent warrants issued in the July 2019 Financing, with limitations on the number of ordinary shares a selling stockholder can beneficially own after exercising the warrants.

POS AM filing: This POS AM filing relates to a purchase agreement with Aspire Capital Fund, LLC, where Aspire Capital is committed to purchase up to an aggregate of $20.0 million of the company's ADSs represented by ordinary shares. The company registered the sale of 1,020,000,000 ordinary shares represented by 10,200,000 ADSs under the Securities Act.

20-F filing | 2245.9M shares outstanding

F-3 filing: This F-3 filing relates to warrants issued in February 2020 private placements. A selling stockholder may not exercise the warrants to the extent such exercise would cause such selling stockholder, together with its affiliates, to beneficially own a number of ordinary shares which would exceed 4.99% or 9.99% of our then outstanding ordinary shares following such exercise.